November 8, 2013 | Bristol-Myers Squibb is making cuts to the clinical development/operations group it acquired when it picked up ZymoGenetics in 2010. The cuts are part of more extended cuts across the company, discontinuing broad based discovery work in hepatitis C, diabetes and neuroscience. Xconomy